Bionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer

About this update from Bionano Genomics, Inc.

[{"type":"text","content":"SAN DIEGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study analyzing optical genome mapping (OGM) as a method to identify homologous recombination deficiency (HRD) in breast cancer samples. The study reported that OGM successfully assessed levels of HRD in all samples, potentially improving genomic profiling of solid tumor samples and offering an efficient, lower-cost method of detecting HRD with greater sensitivity than whole genome sequencing (WGS). In the study, researchers at Institut Curie analyzed fifteen retrospective HRD triple negative breast carcinoma samples from the RadioPARP clinical trial investigating poly ADP ribose polymerase (PARP) inhibitors to assess OGM’s ability to identify HRD tumors, which are associated with a hyper-sensitivity to some classes of drugs, in particular to PARP inhibitors. In this study, OGM identified high numbers of tandem duplication and insertion events and large-scale genomic alterations that are characteristic of HRD, including subclonal variants missed by WGS. Though WGS is commonly used for HRD detection, the study authors highlighted challenges associated with using traditional methods and cited OGM’s robust detection of large structural variants with a high resolution, even in samples with low tumor content, as evidence of its potential application as a first-line method in solid tumor analysis for identification of HRD. “This paper serves as a good demonstration of OGM’s utility for assessing HRD, which is an emerging biomarker used to identify patients who may respond to PARP inhibitors. We believe this study shows that OGM can help overcome the limitations of traditional methods and may capture greater numbers of genomic events reflective of HRD, which we believe may translate into more patients being qualified for life-saving treatments, such as PARP inhibitors,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. This publication can be found here. About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Compa...

More updates from Bionano Genomics, Inc.